Bausch & Lomb (TSX:BLCO) Interest Income : C$20 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Bausch & Lomb's interest income for the three months ended in Dec. 2023 was C$4 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2023 was C$20 Mil.

Bausch & Lomb Interest Income Historical Data

The historical data trend for Bausch & Lomb's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Interest Income Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Income

Get a 7-Day Free Trial

1.32

3.84

8.15

20.12

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Income	Get a 7-Day Free Trial											4.08	4.11	6.64	5.41	4.03

Bausch & Lomb Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$20 Mil.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.